Lisata Therapeutics, Inc. (FRA:8NE)

Lisata Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	1.07	1	-	-	-	-
Gross Profit	1.07	1	-	-	-	-
Selling, General & Admin	11.38	12.08	12.97	14.14	11.47	9.89
Research & Development	9.77	11.33	12.73	13.07	17.58	9.25
Operating Expenses	21.15	23.41	25.71	27.21	29.05	19.15
Operating Income	-20.08	-22.41	-25.71	-27.21	-29.05	-19.15
Interest & Investment Income	1.02	1.88	2.72	1.05	0.15	0.13
Other Non Operating Income (Expenses)	-0.04	-0.16	-0.09	-0.06	-0.08	-
EBT Excluding Unusual Items	-19.1	-20.68	-23.07	-26.21	-28.97	-19.01
Gain (Loss) on Sale of Assets	-0.1	-0.1	-0.1	-0.1	-	-
Pretax Income	-19.2	-20.78	-23.17	-56.7	-28.97	-19.01
Income Tax Expense	-0.96	-0.8	-2.33	-2.48	-1.51	-10.87
Earnings From Continuing Operations	-18.24	-19.99	-20.84	-54.23	-27.47	-8.14
Net Income to Company	-18.24	-19.99	-20.84	-54.23	-27.47	-8.14
Minority Interest in Earnings	-	-	-	-	-	-0.01
Net Income	-18.24	-19.99	-20.84	-54.23	-27.47	-8.15
Net Income to Common	-18.24	-19.99	-20.84	-54.23	-27.47	-8.15
Shares Outstanding (Basic)	9	8	8	5	4	1
Shares Outstanding (Diluted)	9	8	8	5	4	1
Shares Change (YoY)	3.87%	3.17%	55.85%	40.46%	258.29%	49.54%
EPS (Basic)	-2.12	-2.40	-2.58	-10.47	-7.45	-7.92
EPS (Diluted)	-2.12	-2.40	-2.58	-10.47	-7.45	-7.92
Free Cash Flow	-17.26	-19.36	-20.03	-21.46	-22.31	-8.84
Free Cash Flow Per Share	-2.01	-2.32	-2.48	-4.14	-6.05	-8.59
Gross Margin	100.00%	100.00%	-	-	-	-
Operating Margin	-1876.54%	-2240.90%	-	-	-	-
Profit Margin	-1704.86%	-1998.50%	-	-	-	-
Free Cash Flow Margin	-1612.71%	-1935.60%	-	-	-	-
EBITDA	-19.91	-22.24	-25.52	-27.14	-29	-19.08
D&A For EBITDA	0.17	0.17	0.19	0.07	0.06	0.06
EBIT	-20.08	-22.41	-25.71	-27.21	-29.05	-19.15

Source: S&P Global Market Intelligence. Standard template. Financial Sources.